154 related articles for article (PubMed ID: 9083717)
1. Impact of newer antipsychotics on outcomes in schizophrenia.
Keks NA
Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
[TBL] [Abstract][Full Text] [Related]
2. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
[TBL] [Abstract][Full Text] [Related]
3. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
4. Risperidone versus haloperidol: II. Cost-effectiveness.
Davies A; Langley PC; Keks NA; Catts SV; Lambert T; Schweitzer I
Clin Ther; 1998; 20(1):196-213. PubMed ID: 9522115
[TBL] [Abstract][Full Text] [Related]
5. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
6. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS; Heeg B; Buskens E; van Hout BA
Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
9. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
14. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Ganguly R; Miller LS; Martin BC
Schizophr Res; 2003 Sep; 63(1-2):111-9. PubMed ID: 12892865
[TBL] [Abstract][Full Text] [Related]
15. Assessing a drug's cost-benefits.
Raleigh F
Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
[No Abstract] [Full Text] [Related]
16. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Lindner LM; Marasciulo AC; Farias MR; Grohs GE
Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
[TBL] [Abstract][Full Text] [Related]
17. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Chouinard G; Albright PS
J Clin Psychopharmacol; 1997 Aug; 17(4):298-307. PubMed ID: 9241010
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A
Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
